Quality of life in lung cancer patients
Quality of life in lung cancer patients
复制标题
DOI：
10.1093/annonc/12.suppl_3.s21
复制
发表时间：
2001-01-01
影响因子：
50.5
通讯作者：
De Marinis, F
中科院分区：
文献类型：
--
作者：
Gridelli, C;Perrone, F;De Marinis, F
肺癌患者的生活质量受到与患者、疾病分期和治疗特点有关的几个因素的影响。对于小细胞肺癌（SCLC），治疗通常是积极的，主要基于化疗。非小细胞肺癌（NSCLC）的治疗策略强烈依赖于疾病的分期，范围从手术到姑息性化疗。在过去几年中，在生存方面几乎没有取得任何进展。因此，治疗对生活质量的影响已经变得越来越重要。在衡量生活质量的工具中，有一些是专门针对肺癌开发的，如欧洲癌症研究与治疗组织（EORTC） LC-13问卷、癌症治疗功能评估（FACT-L）问卷和肺癌症状量表（LCSS）。到目前为止，很少有随机临床试验能够正确评估生活质量。经常使用未经验证的工具和糟糕的数据分析方法存在明显的缺陷，但生活质量评估是至关重要的，应该通过精心计划和良好实施的前瞻性临床试验来解决。
The quality of life of lung cancer patients is affected by several factors related to the patients, stage of disease and treatment characteristics. For small-cell lung cancer (SCLC), the treatment is generally aggressive, primarily based on chemotherapy. Treatment strategy for non-small-cell lung cancer (NSCLC) is strongly dependent on the stage of the disease and ranges from surgery to palliative chemotherapy. Over the last few years, very little progress has been made in terms of survival. Therefore, the effect of treatment on quality of life has become progressively more relevant. Among the instruments for measuring quality of life, there are some specifically developed for lung cancer, such as the European Organization for Research and Treatment of Cancer (EORTC) LC-13 questionnaire, the Functional Assessment of Cancer Therapy (FACT-L) questionnaire and the Lung Cancer Symptom Scale (LCSS). Up to now, few randomised clinical trials have correctly evaluated quality of life. There are evident pitfalls associated with the use of frequently non-validated tools, and poor methods of data analysis, but quality-of-life evaluation is crucial and should be addressed through well-planned and well-conducted prospective clinical trials.